PublizoomAward notice Supplies
National Contract for Monoclonal Antibody for Respiratory Syncytial Virus (RSV) Passive Immunisation for Infants - Pathfinder Programme 3
- Public buyer
- Health Service Executive (HSE)
Kildare - Place of performance
- Kildare
- Estimated value
- €1 excl. VAT
- Amount awarded
- €1 excl. VAT
- Bids received
- 1
- Procedure
- Negotiated procedure without prior publication
The buyer consulted a few companies directly: it is no longer possible to take part. - Publication
- 1 October 2026
- Notice language
- English
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
In accordance with National Immunisation Advisory Committee (NIAC) advice, HSE Public Health: National Health Protection, with Access & Integration and the National Women and Infants Health Programme wish to put in place a contract for a monoclonal antibody, Nirsevimab (Beyfontus®) for a third pathfinder immunisation programme to protect all babies from RSV disease born from 1st March 2026 to 28th February 2027. RSV is a common virus that causes respiratory infections in young babies. Babies under three months old get sicker with RSV than older children.
Each winter in Ireland one in two newborns babies will get RSV and many will need medical care from their GP or the emergency department of a children’s hospital. Four out of a hundred new born babies are hospitalised due to RSV with some babies needing special treatment in intensive care units. Nirsevimab is currently the best way to protect babies from RSV.
This contract will supply 50,000 doses of this drug for passive immunisation over a seven month period during the RSV season.
Awarded to
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33651600
Winning prices for comparable contracts
- A quarter below
- €1
- Median
- €1
- A quarter above
- €1
Amounts awarded (excl. VAT) over the last 3 years for 6 contracts in the same CPV group (3365…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
| Contract | Winner | Amount |
|---|---|---|
| Supply and Delivery of Live Attenuated Influenza Vaccine (LAIV) 2026/2027 Flu Season Health Service Executive (HSE) · 1 October 2026 |
AstraZeneca AB | €1 |
| Supply and delivery of diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content) Health Service Executive (HSE) · 1 October 2026 |
Sanofi | €1 |
| Supply and Delivery of 6 in 1 (Diphtheria, Tetanus, acellular Pertussis, Hepatitis B, Inactivated Polio Vaccine, Haemophilus Influenza Type B Conjugate) Vaccine Health Service Executive (HSE) · 27 August 2026 |
MSD | €1 |
| Supply and Delivery of Enhanced (adjuvanted) Inactivated Influenza Vaccines for Older People Health Service Executive (HSE) · 26 August 2026 |
Seqirus UK Limited | €1 |
| Supply and Delivery of Human Seasonal Trivalent Influenza Vaccines Health Service Executive (HSE) · 26 August 2026 |
Sanofi Mylan IRE Healthcare Ltd |
€1 |
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 676444-2026.